A PHASE 2 STUDY OF BLINATUMOMAB (NSC# 765986, IND# 125462) IN COMBINATION WITH NIVOLUMAB (NSC # 748726, IND# 125462), A CHECKPOINT INHIBITOR OF PD-1, IN B-ALL PATIENTS AGED >= 1 TO < 31 YEARS OLD WITH FIRST RELAPSE

Registry ID

AALL1821

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

CHILDRENS ONCOLOGY GROUP

Start date

2021-03-09

Last update

2021-02-05

Conditions

• B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Related clinical trials

• AN INTERNATIONAL PILOT STUDY OF CHEMOTHERAPY AND TYROSINE KINASE INHIBITORS WITH BLINATUMOMAB IN PATIENTS WITH NEWLY-DIOGNOSED PHILADELPHIA CHROMOSOME-POSITIVE OR ABL-CLASS PHILADELPHIA CHROMOSOME-LIKE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
• A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ADMINISTRATION OF SUBCUTANEOUS BLINATUMOMAB FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B ALL
• A PHASE III TRIAL TO EVALUATE THE EFFICACY OF THE ADDITION OF INOTUZUMAB OZOGAMICIN (A CONJUGATED ANTI-CD22 MONOCLONAL ANTIBODY) TO FRONTLINE THERAPY IN YOUNG ADULTS (AGES 18-39 YEARS) WITH NEWLY DIAGNOSED PRECURSOR B-CELL ALL
• A PHASE II TRIAL OF TISAGENLECLEUCEL IN FIRST-LINE HIGH-RISK (HR) PEDIATRIC AND YOUNG ADULT PATIENTS WITH B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) WHO ARE MINIMAL RESIDUAL DISEASE (MRD) POSITIVE AT THE END OF CONSOLIDATION (EOC) THERAPY

View on source registry